UroToday7h
SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of ...
UroToday7h
SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants
SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...
UroToday7h
SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis
The cohort had a median age of 65 years (IQR 53–68), with 74% male and 82% Caucasian. Of the total 808 gene panel, 15 genes were mutated by >5% in the entire cohort, with PBRM1, SETD2, KDM5C, TP53, ...
UroToday22h
SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial
Low grade non-muscle invasive bladder cancer (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening Negative voiding cytology for high ...
UroToday1d
SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...
UroToday1d
APCCC Diagnostics 2025: False Positive PSMA PET: What to Know?
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...
UroToday1d
SES AUA 2025: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reversal Thermal Gel
Patients with low-grade upper tract urothelial carcinoma receiving primary treatment with 6 once-weekly pyelocalyceal doses ...
UroToday1d
SES AUA 2025: First-in-Human Study of TAR-210 Erdafitinib Intravesical System in Patients with NMIBC with Select FGFR Alterations
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...
UroToday1d
SES AUA 2025: Survival Outcomes of Radical Prostatectomy versus Dose-Escalated Radiation with ADT in Node-Positive Prostate Cancer
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Arjun Pon Avudaiappan discussing survival outcomes of radical prostatectomy versus dose-escalated radiation with ADT ...
UroToday1d
SES AUA 2025: Characterization of Race-Based Expression within the ERG+ Molecular Subtype in High Grade Prostate Cancer
(UroToday.com) The 2025 SESAUA annual meeting featured a prostate cancer session and a presentation by Matthew Cole discussing gene expression differences and pathway activation by race in ERG ...
UroToday1d
SES AUA 2025: Assessing Hematuria Screening Disparities Using the All of Us Database
(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Jonathan Ryan discussing the assessment of hematuria screening disparities using the All of Us ...
UroToday1d
ASCO GU 2025: Radium-223 Without ADT in Patients with Biochemically Recurrent Prostate Cancer and PET Findings in the Bones
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Melissa Abel discussing radium-223 without androgen deprivation therapy (ADT) in patients ...